[ad_1]
AAfter months of planning, the Louisiana Department of Health has selected a new subsidiary of Gilead Sciences (GILD) to provide a hepatitis C drug based on a payment model called Netflix.
The agreement deals with subscription payments. Asegua Therapeutics, Gilead Unit, has agreed to provide the Medicaid State Program and the Department of Corrections with unrestricted access to an authorized generic version of Epclusa Treatment for a fixed fee for a period of five years. according to the Department of Health. A contract should be finalized by June 1st.
Unlock this item by subscribing to STAT Plus and enjoy your first 30 days for free!
TO START
What is it?
STAT Plus is a premium subscription that offers scalable biopharmaceutical market coverage and in-depth scientific reports from a team with several decades of experience in the industry.
What is included?
- Authoritative coverage and biopharmaceutical analysis, interviews with industry pioneers, policy analysis and first examination of advanced laboratories and early stage research
- Subscriber Networking Events and Group Discussions Across the Country
- Monthly live subscriber discussions with our reporters and experts in the field
- Discounted tickets for industry events and early access to industry reports
[ad_2]
Source link